New hair loss drug combo enters human trials
NCT ID NCT07490327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests two forms of a hair loss drug (AD-303A topical and AD-3031 oral) in 30 men aged 19-55 with male pattern baldness. The goal is to see how the drug moves through the body, how well it works, and if it is safe. The study will help decide the right dose for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tiny needles boost hair growth in balding men?
- A battle for your hair: herbal oil vs. minoxidil serum in a Head-to-Head trial
- Can light boost PRP's power against hair loss?
- Hair loss linked to gut and scalp bacteria in new study
- Baldness breakthrough? own cells injected into scalp to regrow hair
- New laser could spark hair regrowth in balding patients